UK Dermatology Registry of 13 699 Psoriasis pts on biologics (25K biologic exposures) found 1% risk of paradoxical eczema. Biologics included inhibitors of TNF, IL-17, IL12/23, IL-23. Lowest risk w/ IL-23i (0.56/100kPY), and higher w/ IL-17i (1.22) https://t.co/fOX6VGJQLk https://t.co/u1p1sidCte

• Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis

Post-Menopausal Osteoporosis Review and Recommendations A recent New England Journal review of post-menopausal osteoporosis (OP) provided updated information, strategies and a review of guidelines and clinical recommendations. https://t.co/TkJjsX98Ww https://t.co/2Hi72GjEHM

• Post-Menopausal Osteoporosis Review and Recommendations | RheumNow

ICYMI: The Heart of Lupus Few people are aware of the EULAR recommendations1 for cardiovascular (CV) risk management in systemic lupus erythematosus (SLE) published in 2022. The recommendations had 4 overarching principles... https://t.co/5I5eYNqHIu https://t.co/W6VzUFs6kN

• ICYMI: The Heart of Lupus | RheumNow

Withdraw DMARDS after remission? Considering withdrawing DMARDs after remission is on our minds. When patients inquire about tapering or stopping DMARDs while doing well, we often lack a clear-cut answer. https://t.co/wqcCff7kjx https://t.co/vq9ee1dZNX

• Withdraw DMARDS after remission? | RheumNow

Calcineurin Inhibitors in Lupus Nephritis Dr. Kathryn Dao discusses abstract 1509 with Dr. Gabriel Figueroa-Parra at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/1sjvCUyvD9 https://t.co/kocmtM1j6o

• Calcineurin Inhibitors in Lupus Nephritis | RheumNow

Pneumocystis Jiroveci Pneumonia (PJP) Risk https://t.co/OTG9Ud1adu https://t.co/jIhdwws0Un

• Pneumocystis Jiroveci Pneumonia (PJP) Risk | RheumNow

ICYMI: Are Rheumatologists doing Enough for Cervical Cancer? https://t.co/afg5YL3RCN https://t.co/VRyKh6VgmS

• ICYMI: Are Rheumatologists doing Enough for Cervical Cancer? | RheumNow

Even low-dose, short-term steroid use increases the risk of serious CV events Dr. Meral El Ramahi (Nashville, TN) reports on abstract 2430 presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/apgxXeVw1U https://t.co/zPiUCqtJlf

• Even low-dose, short-term steroid use increases the risk of serious CV events |…

ILD Guidelines Indicators to Screen Dr. Mike Putman reports from the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/PDE3eZ0Men https://t.co/7xlwrspq9U

• ILD Guidelines Indicators to Screen | RheumNow

ICYMI: How early is early in PsA? Guidelines for the management of PsA recommend the early referral of patients with the suspected condition for early assessment and treatment. https://t.co/9d6WONarwL https://t.co/lNNKzblkEP

• ICYMI: How early is early in psoriatic arthritis? | RheumNow

Arthritis & Rheumatology has published a new study that suggests knee or hip osteoarthritis patients who are overweight or obese may have less premature death if slow to moderate rate of weight loss results from anti-obesity medications. https://t.co/eSwcybRmX5 https://t.co/xEzMwIvAsK

• Slower Weight Loss May Affect Osteoarthritis Survival | RheumNow

ICYMI: Who gives a ‘JAK’ why and how they work, as long as they do! https://t.co/dXp0bDlnMW https://t.co/k0Jl7EX6zt

• ICYMI: Who gives a ‘JAK’ why and how they work, as long as they do! | RheumNow

Subtype of dermatomyositis is positive for Melanoma differentiation-associated protein 5 (MDA5) antibody. This poor prognosis subtype has distinctive rashes, rapidly progressive interstitial lung disease, lymphopenia &elevated ferritin levels https://t.co/30S4si0Luy https://t.co/xlEVEJMoSp

• Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress

Cardiac Troponin T and MACE Events in RA Dr. Arthur Kavanaugh discusses abstract 0387 at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/6ZcIQzsv4n https://t.co/34fFk3HTWy

• Cardiac Troponin T and MACE Events in RA | RheumNow